Equities analysts expect that Becton, Dickinson and Company (NYSE:BDX) will report earnings of $2.38 per share for the current quarter, according to Zacks. Six analysts have issued estimates for Becton, Dickinson and’s earnings. The lowest EPS estimate is $2.35 and the highest is $2.43. Becton, Dickinson and posted earnings per share of $2.12 during the same quarter last year, which would indicate a positive year over year growth rate of 12.3%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Becton, Dickinson and will report full-year earnings of $9.45 per share for the current financial year, with EPS estimates ranging from $9.41 to $9.47. For the next financial year, analysts expect that the company will report earnings of $10.50 per share, with EPS estimates ranging from $10.33 to $10.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the firm earned $2.35 EPS. The firm’s revenue was down 5.1% compared to the same quarter last year.

Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reiterated an “outperform” rating and issued a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Evercore ISI upgraded shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $186.00 to $200.00 in a research note on Monday, April 24th. Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $195.79.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/20/2-38-eps-expected-for-becton-dickinson-and-company-bdx-this-quarter.html.

In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last three months, insiders sold 57,631 shares of company stock worth $11,112,178. 1.40% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of BDX. Rockland Trust Co. bought a new stake in Becton, Dickinson and during the first quarter valued at about $307,000. Wells Fargo & Company MN boosted its stake in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the last quarter. AMG National Trust Bank boosted its stake in Becton, Dickinson and by 4.2% in the first quarter. AMG National Trust Bank now owns 9,880 shares of the medical instruments supplier’s stock valued at $1,813,000 after buying an additional 401 shares during the last quarter. Boston Financial Mangement LLC boosted its stake in Becton, Dickinson and by 10.2% in the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock valued at $10,218,000 after buying an additional 5,152 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Becton, Dickinson and by 64.2% in the first quarter. Nationwide Fund Advisors now owns 96,582 shares of the medical instruments supplier’s stock valued at $17,717,000 after buying an additional 37,752 shares during the last quarter. 75.57% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and (NYSE BDX) traded down 0.81% during midday trading on Friday, hitting $197.69. The stock had a trading volume of 989,225 shares. The stock’s 50-day moving average is $199.72 and its 200-day moving average is $188.69. Becton, Dickinson and has a one year low of $161.29 and a one year high of $206.63. The company has a market cap of $44.99 billion, a P/E ratio of 57.25 and a beta of 1.05.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.